LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Sanara MedTech Inc. ("Sanara†or the "Company†) (NASDAQ: SMTI) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON SANARA MEDTECH INC. (SMTI), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is the Investigation About? On November 11, 2025, after market hours, Sanara announced that it. ...

SAN FRANCISCO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- On November 7, 2025, The Wall Street Journal reported that Senate Democrats are demanding information related to Fiserv, Inc.’s (NYSE: FI) former CEO and Chairman Frank Bisignano after the company said that it wouldn’t reach financial forecasts set by its former boss. The lawmakers reportedly are seeking information about “Bisignano’s role in developing and approving [Fiserv’s] financial forecasts, his focus on short-term initiatives within the company and an ...

LOS ANGELES, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of HelloFresh SE (“HelloFresh” or the “Company”) (OTC: HELFY, HLFFF) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON HELLOFRESH SE (HELFY, HLFFF), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.   What Is The Investigation About? On November 6, 2025, Grizzly Research published a repo ...

NEW YORK and NEW ORLEANS, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until January 12, 2026 to file lead plaintiff applications in a securities class action lawsuit against Stride, Inc. (“Stride” or the “Company”) (NYSE: LRN), if they purchased or otherwise acquired the Company’s securities between October 22, 2024 and October 28, 2025, inclusive (the “Cl ...

Core Points - A securities class action lawsuit has been filed against James Hardie Industries plc for alleged misleading statements regarding inventory levels and demand during the Class Period from May 20, 2025, to August 18, 2025 [1][2] - The lead plaintiff deadline for investors to join the lawsuit is December 23, 2025 [1][3] Allegations Against Defendants - The complaint alleges that James Hardie misrepresented the strength of demand and the normalcy of stock levels despite knowing about destocking by its North America Fiber Cement distributors [2] - Positive statements made by the company regarding its business operations and prospects were claimed to be materially misleading and lacked a reasonable basis [2] Lead Plaintiff Process - Investors can seek to be appointed as a lead plaintiff representative of the class by the deadline of December 23, 2025, or choose to remain an absent class member [3] - The lead plaintiff will act on behalf of all class members and select counsel to represent the class [3] Law Firm Information - Kessler Topaz Meltzer & Check, LLP is handling the case and has a reputation for prosecuting class actions and recovering significant amounts for victims of corporate misconduct [4]

FCX CLASS ACTION: BFA Law Alerts Freeport-McMoRan Inc. Investors of the Pending Securities Fraud Class Action and Upcoming January 12 DeadlineNovember 18, 2025 3:33 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 18, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Freeport-McMoRan Inc. (NYSE: FCX) and certain of the Company's senior executives for securities fraud after significant ...

Core Viewpoint - A class action securities lawsuit has been filed against RCI Hospitality Holdings, Inc. to recover losses incurred by shareholders due to alleged securities fraud between December 15, 2021, and September 16, 2025 [2][3]. Group 1: Lawsuit Details - The complaint alleges that the defendants engaged in tax fraud and bribery to conceal this fraud, resulting in an understatement of the legal risks facing the company [3]. - It is claimed that the defendants' statements regarding the company's business, operations, and prospects were materially false and misleading, lacking a reasonable basis at all relevant times [3]. Group 2: Next Steps for Shareholders - Shareholders who suffered losses during the specified timeframe, even if they still hold their shares, are encouraged to learn about their rights to seek recovery [4]. Group 3: Legal Firm Background - Levi & Korsinsky LLP has a strong reputation in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [5].

New York, New York--(Newsfile Corp. - November 14, 2025) - If you suffered a loss on your Marex Group plc (NASDAQ: MRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/marex-group-plc-lawsuit-submission-form?prid=177499&wire=5&utm_campaign=1or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.THE LAWSUI ...

Core Viewpoint - A class action securities lawsuit has been filed against Cytokinetics, alleging securities fraud related to misleading statements about the New Drug Application (NDA) for aficamten, which may have led to significant investor losses [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for Cytokinetics investors affected by alleged securities fraud between December 27, 2023, and May 6, 2025 [1]. - Defendants allegedly made materially false statements regarding the NDA submission timeline and FDA approval expectations, claiming approval in the second half of 2025 based on a September 26, 2025, PDUFA date [2]. - The company failed to disclose risks related to not submitting a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process [2]. - During an earnings call on May 6, 2025, it was revealed that the company had discussions with the FDA about safety monitoring but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [2]. Group 2: Next Steps for Investors - Investors who suffered losses in Cytokinetics during the relevant timeframe have until November 17, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky has a strong track record, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action securities lawsuit has been filed against KBR, Inc. alleging securities fraud that affected investors between May 6, 2025, and June 19, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that KBR, Inc. made false statements regarding its partnership with HomeSafe, despite knowing that the U.S. Department of Defense had concerns about HomeSafe's ability to fulfill a global household goods contract [2] - It is alleged that the defendants' statements about KBR's business operations and prospects were materially false and misleading [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until November 18, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]